Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.00 |
---|---|
High | 55.00 |
Low | 55.00 |
Bid | 56.50 |
Offer | 57.00 |
Previous close | 55.00 |
Average volume | 10.50 |
---|---|
Shares outstanding | 89.32m |
Free float | 86.18m |
P/E (TTM) | -- |
Market cap | 5.42bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:01 GMT.
More ▼
Announcements
- Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
- Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
- Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
- Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
More ▼